Relonchem Limited receives Marketing Authorization for its two products

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces that its wholly owned subsidiary Relonchem Limited in UK has received Marketing Authorization for its following products from UK MHRA:

1. Mefenamic Acid 250 mg Film-Coated Tablets
2. Mefenamic Acid 500 mg Film-Coated Tablets

Shares of Marksans Pharma Limited was last trading in BSE at Rs. 192.70 as compared to the previous close of Rs. 188.30. The total number of shares traded during the day was 97728 in over 1508 trades.

The stock hit an intraday high of Rs. 195.80 and intraday low of 189.05. The net turnover during the day was Rs. 18847962.00.

Source : Equity Bulls

Keywords

MarksansPharma INE750C01026 Pharmaceuticals Relonchem UK MarketingAuthorization UKMHRA TwoProducts MefenamicAcid